VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population
- PMID: 32492153
- PMCID: PMC7365686
- DOI: 10.1210/clinem/dgaa311
VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population
Abstract
Context: It is unclear whether vitamin D supplementation reduces risk of falls, and results from randomized controlled trials (RCTs) are conflicting.
Objective: The objective of this work is to determine whether 2000 IU/day of supplemental vitamin D3 decreases fall risk.
Design: VITamin D and OmegA-3 TriaL (VITAL) is a double-blind, placebo-controlled RCT including 25 871 adults, randomly assigned November 2011 to March 2014 and treated for 5.3 years (median).
Setting: This is a nationwide study.
Participants: Men 50 years or older and women 55 years or older (mean age, 67.1 years) without cancer or cardiovascular disease at baseline participated in this study.
Interventions: Interventions included vitamin D3 (cholecalciferol; 2000 IU/day) and/or omega-3 fatty acids (1 g/day) or respective placebos in a 2 × 2 factorial design.
Main outcome measures: Main outcome measures include 2 or more falls and falls resulting in a doctor or hospital visit.
Results: Baseline serum total 25-hydroxyvitamin D (25[OH]D) level was 77 nmol/L; characteristics were well-balanced between groups. Numbers of participants with 2 or more falls were similar between active and placebo groups (9.8% vs 9.4%). Over 5 years, there were no differences in the proportion having 2 or more falls (odds ratio [OR] = 0.97; 95% CI, 0.90-1.05, P = .50), falls resulting in a doctor visit (OR = 1.03; 95% CI, 0.94-1.13, P = .46), or resulting in a hospital visit (OR = 1.04; 95% CI, 0.90-1.19, P = .61) between groups. Results did not differ between those with baseline 25(OH)D less than 50 vs 50 nmol/L or greater or other cut points.
Conclusion: Daily supplemental vitamin D3 vs placebo did not decrease fall risk in generally healthy adults not selected for vitamin D insufficiency. This large RCT does not indicate that supplemental vitamin D should be used for primary prevention of falls in the US population.
Trial registration: ClinicalTrials.gov NCT01747447 NCT01704859.
Keywords: falls; primary prevention; vitamin D.
© Endocrine Society 2020.
Figures
References
-
- Bergen G, Stevens MR, Burns ER. Falls and fall injuries among adults aged ≥ 65 years—United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(37):993-998. - PubMed
-
- Centers for Disease Control and Prevention. National Center for Injury Prevention and Control. Vol 20182016 https://www.cdc.gov/injury/index.html. Accessed 5 2019.
-
- Donald IP, Bulpitt CJ. The prognosis of falls in elderly people living at home. Age Ageing. 1999;28(2):121-125. - PubMed
-
- Mowé M, Haug E, Bøhmer T. Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc. 1999;47(2):220-226. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
